Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis

Journal of Thrombosis and Thrombolysis

Volumn 17, Issue 1, 2004, Pages 35-44

  Corti, Roberto ^a   Hutter, Randolp̈h ^a   Badimon, Juan Jose ^a   Fuster, Valentin ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Inflammation; Thrombosis

Indexed keywords

CELL ADHESION MOLECULE; COLONY STIMULATING FACTOR 1; CYTOKINE; ENZYME; GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; SELECTIN; THROMBOPLASTIN; VASCULAR CELL ADHESION MOLECULE 1;

APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; BLOOD VESSEL OCCLUSION; BLOOD VESSEL WALL; CAUSE OF DEATH; CELL SURVIVAL; CELL TRANSPORT; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; ENZYME RELEASE; EXTRACELLULAR MATRIX; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLAMMATORY CELL; LIPID COMPOSITION; LIPID STORAGE; MACROPHAGE; MORBIDITY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RISK ASSESSMENT; STENOSIS; THROMBOGENESIS; THROMBOSIS; WESTERN HEMISPHERE;

ARTERIOSCLEROSIS; HUMANS; INFLAMMATION; RISK FACTORS; THROMBOSIS;

EID: 4043110643     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:THRO.0000036027.39353.70     Document Type: Article

References (48)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992;326:310-318.
2. Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: Biology Lancet 1999;353(Suppl 2):SII5-SII9.
3. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999 340:115-126.
4. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365-372.
5. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH. Thrombus formation on atherosclerotic plaques: Pathogenesis and clinical consequences. Ann Intern Med 2001;134:224-238.
6. Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. Circulation 1994;90:2126-2146.
7. Stary HC. Composition and classification of human atherosclerotic lesions. Virchows Arch A Pathol Anat Histopathol 1992;421:277-290.
8. Davies MJ. Stability and instability: Two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996 94:2013-2020.
9. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994;90:775-778.
10. Ambrose JA. Angiographic correlations of advanced coronary lesions in acute coronary syndromes. In Fuster V, ed. Syndromes of Atherosclerosis: Correlations of Clinical Imaging and Pathology. Armonk, NY: Futura Publishing Company, Inc. 1996:105-122.
11. Corti R, Fuster V, Badimon JJ, Hutter R, Fayad ZA. New understanding of atherosclerosis (clinically and experimentally) with evolving MRI technology in vivo. Ann NY Acad Sci 2001:181-195.
12. Fuster V. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. Circulation 1994;90:2126-2146.
13. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995;92:1355-1374.
14. Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med 1999;107:85-97.
15. McEver RP, Moore KL, Cummings RD. Leukocyte trafficking mediated by selectin-carbohydrate interactions. J Biol Chem 1995;270:11025-11028.
16. Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001;107:1255-1262.
17. Sartore S, Chiavegato A, Faggin E, et al. Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: From innocent bystander to active participant. Circ Res 2001;89:1111-1121.
18. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995 92:657-671.
19. Michel JB. Contrasting outcomes of atheroma evolution: Intimal accumulation versus medial destruction. Arterioscler Thromb Vasc Biol 2001;21:1389-1392.
20. Silence J, Lupu F, Collen D, Lijnen HR. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol 2001 21:1440-1445.
21. Moreno PR, Purushothaman K-R, Fuster V. Internal elastic lamina in the process of plaque disruption. J Am Coll Cardiol 2001;37:288A-298A.
22. Mallat Z, Tedgui A. Current perspective on the role of apoptosis in atherothrombotic disease. Circ Res 2001;88:998-1003.
23. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997;336:1276-1282.
24. Fernandez-Ortiz A, Badimon JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture. J Am Coll Cardiol 1994 23:1562-1569.
25. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997 95:594-599.
26. Meyer BJ, Badimon JJ, Mailhac A, et al. Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy. Circulation 1994;90:2432-2438.
27. Nemerson Y. Tissue factor and hemostasis. Blood 1988;71:1-8.
28. Moreno PR, Bernardi VH, Lopez-Cuellar J, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996;94:3090-3097.
29. Bauriedel G, Hutter R, Welsch U, Bach R, Sievert H, Luderitz B. Role of smooth muscle cell death in advanced coronary primary lesions: Implications for plaque instability. Cardiovasc Res 1999;41:480-488.
30. Hutter R, Sauter B, Fallon JT, Fuster V, Badimon JJ. Macrophages and vascular stellate cells in human carotid plaques are prone to apoptosis and tissue factor expression. J Am Coll Cardiol 2001;37:288A.
31. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: A role for apoptosis in plaque thrombogenicity Circulation 1999;99:348-353.
32. Badimon JJ, Lettino M, Toschi V et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999;99:1780-1787.
33. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000 20:1262-1275.
34. Dangas G, Badimon JJ, Smith DA, et al. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999;33:1294-1304.
35. Rauch U, Osende JI, Chesebro JH, et al. Statins and cardiovascular diseases: The multiple effects of lipid-lowering therapy by statins. Atherosclerosis 2000;153:181-189.
36. Rauch U, Crandall J, Osende JJ, et al. Increased thrombus formation relates to ambient blood glucose and leukocyte count in diabetes mellitus type 2. Am J Cardiol 2000;86:246-249.
37. Osende JI, Badimon JJ, Fuster V, et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol 2001;38:1307-1312.
38. Fuster V, Gotto AM, Jr. Risk reduction. Circulation 2000;102:IV94-IV102.
39. Corti R, Badimon JJ. Value and/or desirability ofhemorheologic-hemostatic parameter changes as end points in blood lipid regulating trials. Curr Opin Lipidol 2001:629-637.
40. Rao AK, Chouhan V, Chen X, Sun L, Boden G. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes 1999;48:1156-1161.
41. Kaikita K, Ogawa H, Yasue H, et al. Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. Arterioscler Thromb Vasc Biol 1997;17:2232-2237.
42. Saito Y, Wada H, Yamamuro M, et al. Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease. Am J Hematol 1999;61:238-242.
43. Soejima H, Ogawa H, Yasue H, et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999;99:2908-2913.
44. Drew AF, Davenport P, Apostolopoulos J, Tipping PG. Tissue factor pathway inhibitor expression in atherosclerosis. Lab Invest 1997;77:291-298.
45. Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: Another view of thrombosis. Proc Natl Acad Sci USA 1999;96:2311-2315.
46. Ridker PM. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-1818.
47. Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon? Circulation 1999 100:96-102.
48. Pasceri V, Chang J, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001 103:2531-2534.